Neurocrine Biosciences
NBIX
#1372
Rank
NZ$28.33 B
Marketcap
NZ$279.96
Share price
-1.76%
Change (1 day)
13.85%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): NZ$1.51 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$3.70 Billion. In 2025 the company made an earning of NZ$1.27 Billion, an increase over its 2024 earnings that were of NZ$1.11 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.51 B18.17%
2025 NZ$1.27 B14.74%
2024 NZ$1.11 B96.41%
2023 NZ$0.56 B41.13%
2022 NZ$0.40 B73.74%
2021 NZ$0.23 B-8.82%
2020 NZ$0.25 B77.78%
2019 NZ$0.14 B49.83%
2018 NZ$95.3 M-142.57%
2017 -NZ$0.23 Billion-14.73%
2016 -NZ$0.27 Billion53.15%
2015 -NZ$0.18 Billion46.25%
2014 -NZ$0.12 Billion29.66%
2013 -NZ$90.41 Million-3530.8%
2012 NZ$2.63 M-95.73%
2011 NZ$61.73 M
2009 -NZ$86.78 Million-45.38%
2008 -NZ$0.16 Billion-58.87%
2007 -NZ$0.39 Billion87.3%
2006 -NZ$0.21 Billion351.97%
2005 -NZ$45.63 Million-52.09%
2004 -NZ$95.24 Million-10.98%
2003 -NZ$0.11 Billion
2001 -NZ$79.86 Million
1999 -NZ$36.02 Million108.32%
1998 -NZ$17.29 Million
1996 NZ$5.27 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$12.68 B 707.42%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$23.31 B 1,384.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$63.27 B 3,928.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$55.82 M-96.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$76 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$0.28 B-81.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-NZ$15.24 Million-100.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.81 B 78.95%๐Ÿ‡ฌ๐Ÿ‡ง UK